Mojisola Adeyeye, the Director-General of the organization, made the declaration on Friday.
The DG said that NAFDAC isn't favoring Chloroquine for the treatment of COVID-19 yet for clinical preliminaries to discover treatment for the infection.
"NAFDAC isn't favoring Chloroquine as an item that has can be utilized for Coronavirus on the grounds that there is no accommodation to us for enrollment but since it is under clinical preliminaries, NAFDAC supports prescriptions implied for clinical preliminaries.
In this way the medication is being endorsed only for the clinical preliminaries," Adeyeye said.
She, in this manner, approached specialists and analysts that are keen on doing a clinical preliminary on Chloroquine to move toward affirmed outlets.
"At the present time, we have requested that one organization make a bunch of Chloroquine with the end goal of the clinical preliminary," Adeyeye included.
No comments: